Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GS-441524 in Healthy Volunteer
NCT04859244Phase 1Completed
- Sponsor
- Copycat Sciences LLC
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of gs-441524 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Copycat Sciences LLC. Primary endpoint: Emergence of treatment-related adverse events (AEs) at Day 7. Started Jan 2021; status: completed.
02
Drugs
gs-441524
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04859244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859244.